Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuting Li
Institutions:
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
Observed institutions:
Chinese PLA General Hospital,
Second Affiliated Hospital of Zhejiang University,
Chinese People's Liberation Army,
Zhejiang University
ORCID:
0000-0002-5185-137X
Observed ORCIDs:
0000-0002-5185-137X,
0009-0005-5015-4555
OpenAlex ID:
A5138824014
Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2025
·
Sicheng Du
, Ying Zhang
, et al.
·
Molecular Cancer Therapeutics
·
5
Structure-Based Comparative Metabolomics Identifies LysoPE 15:0 as a Candidate Metabolite Marker of Influenza Virus Infection Dynamics
2026
·
Junxiao Wang
, Yuting Li
, et al.
·
Molecules
PDF
Supplementary Table S3 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Supplementary Table S6 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Figure S1 from Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer
2026
·
Yushen Du
, Ramin Salehi-Rad
, et al.
Data from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Figure S5 from Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer
2026
·
Yushen Du
, Ramin Salehi-Rad
, et al.
Figure S3 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Figure S3 from Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer
2026
·
Yushen Du
, Ramin Salehi-Rad
, et al.
Supplementary Table S4 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Figure S2 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Supplementary Table S5 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Figure S4 from Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer
2026
·
Yushen Du
, Ramin Salehi-Rad
, et al.
Supplementary Table S2 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Supplementary Table S1 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Figure S1 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Figure S2 from Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer
2026
·
Yushen Du
, Ramin Salehi-Rad
, et al.
Figure S4 from Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
2026
·
Sicheng Du
, Ying Zhang
, et al.
Show more works
View as search
Works count:
18
Citation count:
5
H-index:
1
I10-index:
Year
Topic
Type